Annual EBITDA
-$20.13 M
-$525.00 K-2.68%
December 31, 2023
Summary
- As of February 7, 2025, VCNX annual EBITDA is -$20.13 million, with the most recent change of -$525.00 thousand (-2.68%) on December 31, 2023.
- During the last 3 years, VCNX annual EBITDA has risen by +$7.92 million (+28.24%).
- VCNX annual EBITDA is now -86.83% below its all-time high of -$10.78 million, reached on December 31, 2016.
Performance
VCNX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$5.71 M
-$103.00 K-1.84%
September 30, 2024
Summary
- As of February 7, 2025, VCNX quarterly EBITDA is -$5.71 million, with the most recent change of -$103.00 thousand (-1.84%) on September 30, 2024.
- Over the past year, VCNX quarterly EBITDA has dropped by -$1.87 million (-48.57%).
- VCNX quarterly EBITDA is now -159.10% below its all-time high of -$2.20 million, reached on December 31, 2017.
Performance
VCNX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$18.45 M
-$827.00 K-4.69%
September 30, 2024
Summary
- As of February 7, 2025, VCNX TTM EBITDA is -$18.45 million, with the most recent change of -$827.00 thousand (-4.69%) on September 30, 2024.
- Over the past year, VCNX TTM EBITDA has increased by +$598.00 thousand (+3.14%).
- VCNX TTM EBITDA is now -241.76% below its all-time high of -$5.40 million, reached on March 31, 2017.
Performance
VCNX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VCNX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.7% | -48.6% | +3.1% |
| 3 y3 years | +28.2% | -15.8% | +7.7% |
| 5 y5 years | +30.4% | -15.8% | +7.7% |
VCNX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.7% | +5.9% | -73.5% | +18.8% | -4.7% | +15.7% |
| 5 y | 5-year | -2.7% | +36.3% | -73.5% | +33.1% | -4.7% | +41.9% |
| alltime | all time | -86.8% | +36.3% | -159.1% | +37.1% | -241.8% | +45.5% |
Vaccinex EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.71 M(+1.8%) | -$18.45 M(+4.7%) |
| Jun 2024 | - | -$5.61 M(+45.9%) | -$17.62 M(-7.5%) |
| Mar 2024 | - | -$3.84 M(+16.8%) | -$19.04 M(-5.4%) |
| Dec 2023 | -$20.13 M(+2.7%) | -$3.29 M(-32.6%) | -$20.13 M(-8.0%) |
| Sep 2023 | - | -$4.88 M(-30.6%) | -$21.88 M(+0.9%) |
| Jun 2023 | - | -$7.03 M(+42.6%) | -$21.68 M(+8.5%) |
| Mar 2023 | - | -$4.93 M(-2.0%) | -$19.98 M(+1.9%) |
| Dec 2022 | -$19.61 M(-8.4%) | -$5.03 M(+7.3%) | -$19.61 M(+2.2%) |
| Sep 2022 | - | -$4.69 M(-12.0%) | -$19.18 M(-1.7%) |
| Jun 2022 | - | -$5.33 M(+17.0%) | -$19.51 M(-1.3%) |
| Mar 2022 | - | -$4.55 M(-1.2%) | -$19.77 M(-7.6%) |
| Dec 2021 | -$21.40 M(-23.7%) | -$4.61 M(-8.4%) | -$21.40 M(-6.3%) |
| Sep 2021 | - | -$5.03 M(-9.9%) | -$22.83 M(-13.3%) |
| Jun 2021 | - | -$5.58 M(-9.8%) | -$26.34 M(-3.1%) |
| Mar 2021 | - | -$6.19 M(+2.5%) | -$27.17 M(-3.2%) |
| Dec 2020 | -$28.05 M | -$6.04 M(-29.2%) | -$28.05 M(-0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$8.53 M(+33.0%) | -$28.28 M(+3.5%) |
| Jun 2020 | - | -$6.41 M(-9.3%) | -$27.32 M(-8.0%) |
| Mar 2020 | - | -$7.07 M(+13.0%) | -$29.71 M(-6.3%) |
| Dec 2019 | -$31.61 M(+9.4%) | -$6.26 M(-17.4%) | -$31.72 M(-6.3%) |
| Sep 2019 | - | -$7.58 M(-13.9%) | -$33.85 M(+3.3%) |
| Jun 2019 | - | -$8.80 M(-3.1%) | -$32.77 M(+7.7%) |
| Mar 2019 | - | -$9.08 M(+8.2%) | -$30.44 M(+5.3%) |
| Dec 2018 | -$28.90 M(+68.1%) | -$8.39 M(+29.1%) | -$28.90 M(+27.2%) |
| Sep 2018 | - | -$6.50 M(+0.5%) | -$22.71 M(+6.5%) |
| Jun 2018 | - | -$6.47 M(-14.2%) | -$21.33 M(+10.3%) |
| Mar 2018 | - | -$7.54 M(+242.2%) | -$19.34 M(+12.5%) |
| Dec 2017 | -$17.20 M(+59.6%) | -$2.20 M(-57.0%) | -$17.20 M(+14.7%) |
| Sep 2017 | - | -$5.12 M(+14.5%) | -$14.99 M(+51.9%) |
| Jun 2017 | - | -$4.47 M(-17.1%) | -$9.87 M(+82.9%) |
| Mar 2017 | - | -$5.40 M | -$5.40 M |
| Dec 2016 | -$10.78 M | - | - |
FAQ
- What is Vaccinex annual EBITDA?
- What is the all time high annual EBITDA for Vaccinex?
- What is Vaccinex annual EBITDA year-on-year change?
- What is Vaccinex quarterly EBITDA?
- What is the all time high quarterly EBITDA for Vaccinex?
- What is Vaccinex quarterly EBITDA year-on-year change?
- What is Vaccinex TTM EBITDA?
- What is the all time high TTM EBITDA for Vaccinex?
- What is Vaccinex TTM EBITDA year-on-year change?
What is Vaccinex annual EBITDA?
The current annual EBITDA of VCNX is -$20.13 M
What is the all time high annual EBITDA for Vaccinex?
Vaccinex all-time high annual EBITDA is -$10.78 M
What is Vaccinex annual EBITDA year-on-year change?
Over the past year, VCNX annual EBITDA has changed by -$525.00 K (-2.68%)
What is Vaccinex quarterly EBITDA?
The current quarterly EBITDA of VCNX is -$5.71 M
What is the all time high quarterly EBITDA for Vaccinex?
Vaccinex all-time high quarterly EBITDA is -$2.20 M
What is Vaccinex quarterly EBITDA year-on-year change?
Over the past year, VCNX quarterly EBITDA has changed by -$1.87 M (-48.57%)
What is Vaccinex TTM EBITDA?
The current TTM EBITDA of VCNX is -$18.45 M
What is the all time high TTM EBITDA for Vaccinex?
Vaccinex all-time high TTM EBITDA is -$5.40 M
What is Vaccinex TTM EBITDA year-on-year change?
Over the past year, VCNX TTM EBITDA has changed by +$598.00 K (+3.14%)